Enzon Pharmaceuticals, Inc. (OTCMKTS:ENZN) Short Interest Up 406.3% in January

Posted by Doug Madison on Jan 29th, 2025

Enzon Pharmaceuticals, Inc. (OTCMKTS:ENZN – Get Free Report) saw a large increase in short interest in January. As of January 15th, there was short interest totalling 8,100 shares, an increase of 406.3% from the December 31st total of 1,600 shares. Based on an average trading volume of 356,600 shares, the days-to-cover ratio is presently 0.0 days.

Enzon Pharmaceuticals Stock Performance

ENZN stock opened at $0.13 on Wednesday. The firm has a 50 day moving average price of $0.13 and a 200-day moving average price of $0.13. Enzon Pharmaceuticals has a 52-week low of $0.06 and a 52-week high of $0.24. The firm has a market capitalization of $9.51 million, a price-to-earnings ratio of 13.75 and a beta of 0.27.

Enzon Pharmaceuticals Company Profile

(Get Free Report)

Enzon Pharmaceuticals, Inc, together with its subsidiaries, does not have significant operations. Previously, the company marketed its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs.